We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+21.02%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$252M
AUM Growth
-$53.9M
(-18%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-28.78%
Top 10 Holdings %
Top 10 Hldgs %
66.57%
Holding
44
New
15
Increased
7
Reduced
6
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$24.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$15M |
| 3 |
Merck
MRK
|
+$13.8M |
| 4 |
SkinHealth Systems
SKIN
|
+$11.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$38.3M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$15.9M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$15.3M |
| 4 |
Johnson & Johnson
JNJ
|
+$14.1M |
| 5 |
Cigna
CI
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.29% |
| 2 | Consumer Staples | 5.21% |
| 3 | Financials | 2.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.6M | 11.38% |
261,500
+3,736
| +1% | +$388K |
|
|
2
Baxter International
BAX
$11.7B
| $25.1M | 9.98% |
+312,400
| New | +$24.7M |
|
|
WBA
3
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $16.5M | 6.54% |
350,000
-650,000
| -65% | -$31.3M |
|
|
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
| $16.4M | 6.5% |
+96,307
| New | +$15M |
|
|
WBA
5
DELISTED
Walgreens Boots Alliance
WBA
| $14.7M | 5.85% |
312,847
-112,824
| -27% | -$5.44M |
|
6
Edwards Lifesciences
EW
$49.4B
| $13.9M | 5.53% |
122,880
+74,613
| +155% | +$8.52M |
|
|
7
Merck
MRK
$315B
| $13.7M | 5.43% |
+181,765
| New | +$13.8M |
|
|
8
SkinHealth Systems
SKIN
$109M
| $13.1M | 5.21% |
+504,606
| New | +$11.1M |
|
9
Medtronic
MDT
$106B
| $13M | 5.18% |
104,070
-80,610
| -44% | -$10.4M |
|
|
10
Sarepta Therapeutics
SRPT
$1.82B
| $12.5M | 4.96% |
+135,055
| New | +$10.4M |
|
|
11
CALL
Merck
MRK
$315B
| $11.3M | 4.49% |
+150,500
| New | +$11.4M |
|
12
Legend Biotech
LEGN
$4.31B
| $8.52M | 3.39% |
+168,467
| New | +$7.01M |
|
|
13
Regeneron Pharmaceuticals
REGN
$70.9B
| $8.44M | 3.35% |
13,950
-61,677
| -82% | -$38.3M |
|
|
CYPH
14
Cypherpunk Technologies Inc
CYPH
$75.4M
| $7.26M | 2.89% |
+181,067
| New | +$3.41M |
|
|
EGRX
15
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $6.83M | 2.72% |
122,503
+27,581
| +29% | +$1.36M |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.13M | 2.44% |
377,708
+280,888
| +290% | +$3.06M |
|
17
United Therapeutics
UTHR
$22.7B
| $6.06M | 2.41% |
+32,851
| New | +$6.47M |
|
|
BLU
18
DELISTED
BELLUS Health Inc.
BLU
| $5.97M | 2.37% |
972,997
+597,477
| +159% | +$2.27M |
|
|
CCXI
19
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
| $4.73M | 1.88% |
+276,400
| New | +$4.31M |
|
20
Xenon Pharmaceuticals
XENE
$6.6B
| $4.04M | 1.6% |
+264,134
| New | +$4.59M |
|
21
CALL
Novavax
NVAX
$1.35B
| $4M | 1.59% |
+19,300
| New | +$4.25M |
|
|
BGMS
22
Bio Green Med Solution Inc
BGMS
$5.23M
| $2.76M | 1.1% |
145
+58
| +67% | +$1.12M |
|
|
SNCE
23
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $2.58M | 1.03% |
13,164
-330
| -2% | -$65.8K |
|
24
BioNTech
BNTX
$23.1B
| $1.5M | 0.6% |
+5,506
| New | +$1.75M |
|
|
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.45M | 0.58% |
148,355
-165,440
| -53% | -$1.3M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q3 2021 Portfolio in Review
As of Q3 2021, Tri Locum Partners held 44 positions worth $252M, down 18% from $306M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Tri Locum Partners withdrew a net $72.4M in Q3 2021, closing 16 positions and reducing 6 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $15.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 78% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, Tri Locum Partners opened a new position in Baxter International worth $25.1M.
- Tri Locum Partners's largest Q3 2021 buy was Baxter International: 312,400 shares worth $25.1M.
- Tri Locum Partners added most to Edwards Lifesciences in Q3 2021, an estimated $8.52M increase.
- Tri Locum Partners's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $38.3M.
- Tri Locum Partners fully exited Jazz Pharmaceuticals in Q3 2021, selling an estimated $15.9M.
- Tri Locum Partners's ten largest holdings make up 67% of its $252M portfolio in Q3 2021.
- Tri Locum Partners opened 15 new positions and closed 16 in Q3 2021.
- Tri Locum Partners's portfolio value fell 18% quarter-over-quarter to $252M.
Based on Tri Locum Partners's 13F filing for Q3 2021, filed 15 Nov 2021.